2001Drug Metabolism and PharmacokineticsOpen access

Genetic Polymorphism of Drug Transporters.

Ikumi Tamai, Yoshimichi Sai, Jun‐ichi Nezu, Asuka Oku, Miyuki Shimane, Akio Koizumi, Akira Tsuji

Open full text 0 citations

Abstract

In the present study, we examined the genetic polymorphism in drug transporters, using organic cation/carnitine transporter OCTN2 as a model transporter. Since OCTN2 plays a role in carnitine transport by mediating especially a renal reabsorption of carnitine from urine, free carnitine concentrations in blood and urine were used for phenotyping of the genetic mutation of OCTN2. From general population (n=973), the phenotyping resulted in 46 people with significantly low blood free carnitine concentration. Among them 36 people and 69 normal people were further examined for their free carnitine concentration and OCTN2 genes. Only from the group that showed a low carnitine blood concentration, three kinds of heterozygous mutations of OCTN2 gene that show functional loss were found. Furthermore, based on the phenotype observed by systemic carnitine deficiency patients and their family, many type of mutations in OCTN2 were found with functional loss. So, phenotyping of OCTN2 gene by blood and urinary concentration of carnitine is a efficient way to identify the polymorphism of OCTN2 that shows functional alteration. Since OCTN2 was suggested to be involved in renal excretion of organic cations such as tetraethylammonium, genetic polymorphisms that cause functional alteration in carnitine transport may change the pharmacokinetics of organic cations. However, the OCTN2-mediated transport mechanism in carnitine transport is different from that of organic cations in terms of sodium ion dependency, the functional alterations of carnitine transport activity by genetic polymorphism are not necessarily cause the same effect on the pharmacokinetics of organic cations. In addition to OCTN2, we found genetic polymorphism in organic anion transporter OATP-C, which is an important transporter for hepatic excretion of anionic drugs in human. So, we need further functional analysis of various alleles of transporter genes for the better understanding of inter-individual differences of pharmacokinetic characteristics of drugs.

Open-access reader

About this research paper

What this paper is about

In the present study, we examined the genetic polymorphism in drug transporters, using organic cation/carnitine transporter OCTN2 as a model transporter. Since OCTN2 plays a role in carnitine transport by mediating especially a renal reabsorption of carnitine from urine, free carnitine concentrations in blood and urine were used for phenotyping of the genetic mutation of OCTN2. From general population (n=973), the phenotyping resulted in 46 people with significantly low blood free carnitine concentration. Among them 36 people and 69 normal people were further examined for their free carnitine concentration and OCTN2 genes. Only from the group that showed a low carnitine blood concentration, three kinds of heterozygous mutations of OCTN2 gene that show functional loss were found. Furthermore, based on the phenotype observed by systemic carnitine deficiency patients and their family, many type of mutations in OCTN2 were found with functional loss. So, phenotyping of OCTN2 gene by blood and urinary concentration of carnitine is a efficient way to identify the polymorphism of OCTN2 that shows functional alteration. Since OCTN2 was suggested to be involved in renal excretion of organic cations such as tetraethylammonium, genetic polymorphisms that cause functional alteration in carnitine transport may change the pharmacokinetics of organic cations. However, the OCTN2-mediated transport mechanism in carnitine transport is different from that of organic cations in terms of sodium ion dependency, the functional alterations of carnitine transport activity by genetic polymorphism are not necessarily cause the same effect on the pharmacokinetics of organic cations. In addition to OCTN2, we found genetic polymorphism in organic anion transporter OATP-C, which is an important transporter for hepatic excretion of anionic drugs in human. So, we need further functional analysis of various alleles of transporter genes for the better understanding of inter-individual differences of pharmacokinetic characteristics of drugs.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In the present study, we examined the genetic polymorphism in drug transporters, using organic cation/carnitine transporter OCTN2 as a model transporter. Since OCTN2 plays a role in carnitine transport by mediating especially a renal reabsorption of carnitine from urine, free carnitine concentrations in blood and urine were used for phenotyping of the genetic mutation of OCTN2. From general population (n=973), the phenotyping resulted in 46 people with significantly low blood free carnitine concentration. Among them 36 people and 69 normal people were further examined for their free carnitine concentration and OCTN2 genes. Only from the group that showed a low carnitine blood concentration, three kinds of heterozygous mutations of OCTN2 gene that show functional loss were found. Furthermore, based on the phenotype observed by systemic carnitine deficiency patients and their family, many type of mutations in OCTN2 were found with functional loss. So, phenotyping of OCTN2 gene by blood and urinary concentration of carnitine is a efficient way to identify the polymorphism of OCTN2 that shows functional alteration. Since OCTN2 was suggested to be involved in renal excretion of organic cations such as tetraethylammonium, genetic polymorphisms that cause functional alteration in carnitine transport may change the pharmacokinetics of organic cations. However, the OCTN2-mediated transport mechanism in carnitine transport is different from that of organic cations in terms of sodium ion dependency, the functional alterations of carnitine transport activity by genetic polymorphism are not necessarily cause the same effect on the pharmacokinetics of organic cations. In addition to OCTN2, we found genetic polymorphism in organic anion transporter OATP-C, which is an important transporter for hepatic excretion of anionic drugs in human. So, we need further functional analysis of various alleles of transporter genes for the better understanding of inter-individual differences of pharmacokinetic characteristics of drugs.

Key concepts: Carnitine, Organic cation transport proteins, Polymorphism (computer science), Transporter, Pharmacokinetics, Population, Biology, Chemistry

Related papers

Back to paper searchBrowse research topicsOriginal source
Genetic Polymorphism of Drug Transporters. — Research Paper | ScholarLens